Biyazin Yalemgeta, Wondwossen Kalkidan, Wubie Azene Bantie, Getachew Melese, Gebremichael Bereket
School of Nursing and Midwifery, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Department of Pediatrics and Child Health Nursing, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.
J Pharm Policy Pract. 2022 Aug 17;15(1):48. doi: 10.1186/s40545-022-00448-6.
Human immunodeficiency virus and acquired immunodeficiency syndrome had created enormous challenges worldwide, and continues to be the world's serious health and development challenges. Globally, at the end 2017, there were 1.8 million children (< 15 years) living with HIV. The survival of HIV-positive children treated with ART depends on a variety of factors, which might vary greatly with economic, socio-demographic, behavioral risk, and health factors. This study aimed to assess survival status and predictors of mortality among HIV-positive children on antiretroviral therapy at East Gojjam Zone Public hospitals, Northwest Ethiopia.
An institution-based retrospective cohort study was conducted in selected hospitals of the East Gojjam zone, Northwest Ethiopia, among < 15-year-old children who were newly enrolled in HIV care clinic from January 1st, 2014 to December 31, 2018. Data were collected from patient charts from March 1 to 22, 2019 using a standardized checklist. Data were analyzed by SPSS version 24. A Kaplan-Meier curve and log-rank test were used to estimate the survival time and compare survival curves between variables. Multivariable Cox proportional-hazards model was fitted to identify predictors of survival status taking p-value < 0.05 as statistically significant.
In this study, a total of 251 HIV-positive children on ART were followed up for a total of 60 months, with a mean survival time of 55.54 (± 0.83) (95% CI: 53.90-57.17) months. The overall mortality incidence rate in the cohort during the 626 Child-Year-Observation (CYO) was 2.56/100 CYO. The overall estimated survival probability after starting ART was 0.90 at 60 months of follow-up. In this study age < 5 years, Hgb < 10 gm/dl, CD4 count below threshold, cotrimoxazole preventive therapy, and subnormal weight for height were statistically significant predictors of survival status (P < 0.05).
Age, hemoglobin level, CD4 count, weight for height, and not taking cotrimoxazole preventive therapy were independent predictors of mortality. Therefore, concerned stakeholders should focus on the above-mentioned predictors of mortality and nutritional interventions to enhance the survival of HIV-infected children on antiretroviral therapy.
人类免疫缺陷病毒和获得性免疫缺陷综合征在全球范围内带来了巨大挑战,并且仍然是世界严重的健康和发展挑战。在全球范围内,2017年底,有180万儿童(<15岁)感染艾滋病毒。接受抗逆转录病毒治疗(ART)的艾滋病毒阳性儿童的生存取决于多种因素,这些因素可能因经济、社会人口统计学、行为风险和健康因素而有很大差异。本研究旨在评估埃塞俄比亚西北部东戈贾姆地区公立医院接受抗逆转录病毒治疗的艾滋病毒阳性儿童的生存状况和死亡预测因素。
在埃塞俄比亚西北部东戈贾姆地区的选定医院进行了一项基于机构的回顾性队列研究,研究对象为2014年1月1日至2018年12月31日新登记到艾滋病毒护理诊所的<15岁儿童。2019年3月1日至22日使用标准化检查表从患者病历中收集数据。数据采用SPSS 24版进行分析。使用Kaplan-Meier曲线和对数秩检验来估计生存时间并比较变量之间的生存曲线。采用多变量Cox比例风险模型来确定生存状况的预测因素,将p值<0.05视为具有统计学意义。
在本研究中,共有251名接受抗逆转录病毒治疗的艾滋病毒阳性儿童接受了总共60个月的随访,平均生存时间为55.54(±0.83)(95%置信区间:53.90 - 57.17)个月。在626儿童年观察期(CYO)内,该队列中的总体死亡率发病率为2.56/100 CYO。开始抗逆转录病毒治疗后60个月的总体估计生存概率为0.90。在本研究中,年龄<5岁、血红蛋白<10 g/dl、CD4计数低于阈值、复方新诺明预防性治疗以及身高别体重低于正常水平是生存状况的统计学显著预测因素(P<0.05)。
年龄、血红蛋白水平、CD4计数、身高别体重以及未接受复方新诺明预防性治疗是死亡的独立预测因素。因此,相关利益攸关方应关注上述死亡预测因素和营养干预措施,以提高接受抗逆转录病毒治疗的艾滋病毒感染儿童的生存率。